A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Advanced Search

You could also try: concerning (1000)

Finance and Investment Committee ToR April 2022

Description
Finance and Investment Committee Terms of Reference Date Issued: Review Date: Document Type: 1 April 2022 November
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2022-Trust-documents/Finance-and-Investment-Committee-ToR-April-2022.pdf

DVdSC (weekly cycles 9 onwards) DaratumumabSC-Bortezomib-Dexamethasone Ver1

Description
Chemotherapy Protocol Myeloma DVd SC (weekly) Bortezomib Daratumumab Dexamethasone Cycles 9 onwards Regimen • Myeloma – Bortezomib with daratumumab and dexamethasone In
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/DVdSC-weekly-cycles-9-onwards-DaratumumabSC-Bortezomib-Dexamethasone-Ver1.pdf

Cabozantinib

Description
Chemotherapy Protocol RENAL CELL CANCER Regimen CABOZANTINIB • Renal Cell – Cabozantinib (60mg-tablets) Indication • Cabozantinib s indicated for the treatment
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Renal-cell/Cabozantinib.pdf

Obinutuzumab_maintenance

Description
Chemotherapy Protocol Non-Hodgkin Lymphoma Obinutuzumab (Maintenance) Regimen • NHL – Obinutuzumab (Maintenance) Indication • Obinutuzumab in combi
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Obinutuzumab-maintenance.pdf

InP-BEAM

Description
Chemotherapy Protocol LYMPHOMA CARMUSTINE-CYTARABINE-ETOPOSIDE (split)-MELPHALAN (BEAM) Inpatient Regimen Regimen Lymphoma – InP-BEAM (split)
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/InP-BEAM.pdf

InP-PAM-(cycles 5-6) v1

Description
Chemotherapy Protocol Sarcoma DOXORUBICIN-METHOTREXATE (cycles 5-6) Inpatient Regimen There are multiple versions of this protocol in use.
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Sarcoma/InP-PAM-cycles-5-6-v1.pdf

InP Doxorubicin Etoposide Ifosfamide Vincristine VIDEVer1

Description
Chemotherapy Protocol SARCOMA DOXORUBICIN-ETOPOSIDE-IFOSFAMIDE -VINCRISTINE (VIDE) Inpatient Regimen Regimen Sarcoma-InP- Doxorubicin-Etoposide-Ifosfamide-Vincristine (VIDE) Indication Ewings Sarcoma
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Sarcoma/InPDoxorubicinEtoposideIfosfamideVincristineVIDEVer1.pdf

InP Cyclophosphamide Doxorubicin Etoposide Vincristine VCDEVer1

Description
Chemotherapy Protocol SARCOMA DOXORUBICIN-CYCLOPHOSPHAMIDE-ETOPOSIDE-VINCRISTINE (VCDE) Inpatient Regimen Regimen Sarcoma-InP- Cyclophosphamide-Doxorubicin-Etoposide-Vincristine (VCDE) Indication Rhabdommyosarcoma Toxicity
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Sarcoma/InPCyclophosphamideDoxorubicinEtoposideVincristineVCDEVer1.pdf

Von Hippel-Lindau disease (VHL) - patient information

Description
Information about von Hippel-Lindau (VHL) disease.
Url
/Media/UHS-website-2019/Patientinformation/Genetics/Von-Hippel-Lindau-disease-VHL-1438-PIL.pdf

CH003 SOP regimen validation full

Description
Standard Operating Procedure Validation of Chemotherapy Protocols in ARIA (Wessex) (SOP:CH003) 1.
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Validation/CH003-SOP-regimen-validation-full.pdf
281 to 290 of 327
Previous … 27 28 29 30 31 … Next